Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Array of cutaneous adverse effects associated with sorafenib.

× No keyword cloud information.

5 in total

1. Leukocytoclastic vasculitis masquerading as hand-foot syndrome in a patient treated with sorafenib.

Authors: Nancy M Chung; Martin Gutierrez; Maria L Turner
Journal: Arch Dermatol Date: 2006-11

2. Sorafenib-induced eruptive melanocytic lesions.

Authors: Heidi H Kong; Vincent Sibaud; Maria L Chanco Turner; Tito Fojo; Thomas J Hornyak; Christine Chevreau
Journal: Arch Dermatol Date: 2008-06

3. Hand-foot skin reaction increases with cumulative sorafenib dose and with combination anti-vascular endothelial growth factor therapy.

Authors: Nilofer S Azad; Jeanny B Aragon-Ching; William L Dahut; Martin Gutierrez; William D Figg; Lokesh Jain; Seth M Steinberg; Maria L Turner; Elise C Kohn; Heidi H Kong
Journal: Clin Cancer Res Date: 2009-02-15 Impact factor: 12.531

4. Prospective study of the cutaneous adverse effects of sorafenib, a novel multikinase inhibitor.

Authors: Julien Autier; Bernard Escudier; Janine Wechsler; Alain Spatz; Caroline Robert
Journal: Arch Dermatol Date: 2008-07

Review 5. Dermatologic symptoms associated with the multikinase inhibitor sorafenib.

Authors: Caroline Robert; Christina Mateus; Alain Spatz; Janine Wechsler; Bernard Escudier
Journal: J Am Acad Dermatol Date: 2008-11-25 Impact factor: 11.527

5 in total

8 in total

1. Harvesting the low-hanging fruit: kinase inhibitors for therapy of advanced medullary and nonmedullary thyroid cancer.

Authors: James A Fagin; R Michael Tuttle; David G Pfister
Journal: J Clin Endocrinol Metab Date: 2010-06 Impact factor: 5.958

Review 2. Hyperkeratotic Skin Adverse Events Induced by Anticancer Treatments: A Comprehensive Review.

Authors: Maria Vastarella; Gabriella Fabbrocini; Vincent Sibaud
Journal: Drug Saf Date: 2020-05 Impact factor: 5.606

Review 3. Dermatological adverse events from BRAF inhibitors: a growing problem.

Authors: Viswanath Reddy Belum; Alyssa Fischer; Jennifer Nam Choi; Mario E Lacouture
Journal: Curr Oncol Rep Date: 2013-06 Impact factor: 5.075

Review 4. Potentially life‑threatening severe cutaneous adverse reactions associated with tyrosine kinase inhibitors (Review).

Authors: Emily L Coleman; Brianna Olamiju; Jonathan S Leventhal
Journal: Oncol Rep Date: 2020-12-24 Impact factor: 3.906

5. Sorafenib-associated facial acneiform eruption.

Authors: Philip R Cohen
Journal: Dermatol Ther (Heidelb) Date: 2014-12-25

6. Pharmacological control of receptor of advanced glycation end-products and its biological effects in psoriasis.

Authors: A V Mezentsev; S A Bruskin; A G Soboleva; V V Sobolev; E S Piruzian
Journal: Int J Biomed Sci Date: 2013-09

7. Vandetanib-eluting Radiopaque Beads: In vivo Pharmacokinetics, Safety and Toxicity Evaluation following Swine Liver Embolization.

Authors: Alban Denys; Peter Czuczman; David Grey; Zainab Bascal; Rhys Whomsley; Hugh Kilpatrick; Andrew L Lewis
Journal: Theranostics Date: 2017-06-01 Impact factor: 11.556

8. Nodular-cystic eruption in course of sorafenib administration for hepatocarcinoma: An unconventional skin reaction requiring unconventional treatment.

Authors: Francesco Borgia; Carlo Saitta; Mario Vaccaro; Maria Stella Franzè; Maria Lentini; Serafinella Patrizia Cannavò
Journal: Int J Immunopathol Pharmacol Date: 2017-08-21 Impact factor: 3.219

8 in total